The Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medication, Bevatas, to the market. This decision overturns a previous block on the drug, affirming the court's view that Bevatas and Sun Pharma's Bevetex are sufficiently different in their ingredients and intended use.